NCT05672537 2023-01-05Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskTianjin Medical University Cancer Institute and HospitalPhase 2 Unknown70 enrolled